Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Rating Upgraded by HC Wainwright

HC Wainwright upgraded shares of Tarsus Pharmaceuticals (NASDAQ:TARS - Free Report) to a buy rating in a research report released on Tuesday, Marketbeat Ratings reports. The firm currently has $72.00 price target on the stock. HC Wainwright also issued estimates for Tarsus Pharmaceuticals' Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($1.60) EPS, FY2026 earnings at ($2.10) EPS, FY2027 earnings at $0.76 EPS, FY2028 earnings at $0.44 EPS and FY2029 earnings at $0.89 EPS.

Several other analysts have also issued reports on TARS. Guggenheim boosted their target price on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Jefferies Financial Group boosted their price objective on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. Wall Street Zen cut Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 22nd. The Goldman Sachs Group lifted their target price on Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a research report on Monday, May 5th. Finally, Barclays reduced their price target on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Tarsus Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $66.17.

Tarsus Pharmaceuticals Stock Performance

Shares of TARS stock traded down $0.50 on Tuesday, reaching $42.94. The stock had a trading volume of 428,338 shares, compared to its average volume of 703,683. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. Tarsus Pharmaceuticals has a 1 year low of $20.08 and a 1 year high of $57.28. The stock has a market cap of $1.80 billion, a P/E ratio of -11.27 and a beta of 0.94. The company has a 50 day simple moving average of $46.93 and a 200 day simple moving average of $48.92.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.05. The business had revenue of $78.34 million for the quarter, compared to analysts' expectations of $72.50 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. Equities research analysts expect that Tarsus Pharmaceuticals will post -3.17 EPS for the current year.

Insider Transactions at Tarsus Pharmaceuticals

In related news, CEO Bobak R. Azamian sold 8,534 shares of the stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $50.11, for a total transaction of $427,638.74. Following the completion of the transaction, the chief executive officer now directly owns 53,635 shares of the company's stock, valued at approximately $2,687,649.85. This represents a 13.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Dianne C. Whitfield sold 2,315 shares of the firm's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $107,161.35. Following the transaction, the insider now owns 50,751 shares of the company's stock, valued at $2,349,263.79. This represents a 4.36% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 32,542 shares of company stock valued at $1,581,173 over the last 90 days. Company insiders own 8.25% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of TARS. Paradigm Biocapital Advisors LP lifted its position in Tarsus Pharmaceuticals by 3.1% during the first quarter. Paradigm Biocapital Advisors LP now owns 2,610,197 shares of the company's stock valued at $134,086,000 after purchasing an additional 78,301 shares during the last quarter. Jennison Associates LLC lifted its holdings in shares of Tarsus Pharmaceuticals by 14.8% in the 4th quarter. Jennison Associates LLC now owns 2,500,132 shares of the company's stock valued at $138,432,000 after acquiring an additional 321,552 shares during the last quarter. Vanguard Group Inc. increased its stake in Tarsus Pharmaceuticals by 5.3% during the first quarter. Vanguard Group Inc. now owns 2,226,595 shares of the company's stock worth $114,380,000 after acquiring an additional 111,433 shares during the last quarter. Toronto Dominion Bank purchased a new stake in Tarsus Pharmaceuticals during the fourth quarter valued at approximately $105,714,000. Finally, Lord Abbett & CO. LLC lifted its stake in shares of Tarsus Pharmaceuticals by 4.0% in the 1st quarter. Lord Abbett & CO. LLC now owns 1,331,701 shares of the company's stock valued at $68,409,000 after purchasing an additional 51,714 shares during the last quarter. 90.01% of the stock is currently owned by institutional investors.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.